false 0001509745 0001509745 2024-07-02 2024-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(D)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 2, 2024

 

Leap Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-37990   27-4412575
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

47 Thorndike Street, Suite B1-1
Cambridge, MA 		02141
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617) 714-0360

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 LPTX Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

(a)            Leap Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on July 2, 2024.

 

(b)            The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

 

(1) The following director nominees were elected to serve as Class I directors until the Company’s 2027 annual meeting of stockholders and until their successors are duly elected and qualified.

 

Nominee  Votes For  Votes Withheld  Broker Non-Votes
James Cavanaugh  16,740,789  1,392,072  7,871,104
Douglas E. Onsi  17,084,768  1,048,093  7,871,104
Christian Richard  17,809,064  323,797  7,871,104
Richard Schilsky  16,813,357  1,319,504  7,871,104

 

(2) The Company’s stockholders approved, on an advisory basis, the executive compensation of the Company’s named executive officers.

 

Votes For  Votes Against  Votes Abstaining  Broker Non-Votes
16,820,682  1,272,059  40,120  7,871,104

 

(3) The Amendment to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan was approved.

 

Votes For  Votes Against  Votes Abstaining  Broker Non-Votes
16,572,103  1,480,150  80,608  7,871,104

 

(4) The appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.

 

Votes For  Votes Against  Votes Abstaining
25,894,496  71,613  37,856

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LEAP THERAPEUTICS, INC.
   
   
Dated: July 8, 2024 By: /s/ Douglas E. Onsi
  Name: Douglas E. Onsi
  Title: Chief Executive Officer and President

 

 

v3.24.2
Cover
Jul. 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 02, 2024
Entity File Number 001-37990
Entity Registrant Name Leap Therapeutics, Inc.
Entity Central Index Key 0001509745
Entity Tax Identification Number 27-4412575
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 47 Thorndike Street
Entity Address, Address Line Two Suite B1-1
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code 617
Local Phone Number 714-0360
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol LPTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Leap Therapeutics Charts.
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Leap Therapeutics Charts.